Literature DB >> 32058626

Transcatheter closure vs totally endoscopic robotic surgery for atrial septal defect closure: A single-center experience.

Ersin Kadirogullari1, Burak Onan1, Baris Timur1, Ali Birant2, Adem Reyhancan1, Serdar Basgoze1, Unal Aydin1.   

Abstract

BACKGROUND: Transcatheter closure is the preferred method for atrial septal defect (ASD) closure. Robotic surgery has become the least invasive technique for ASD closure. Therefore, we sought to evaluate the outcomes in patients who underwent ASD closure with transcatheter or robotic surgery techniques.
METHODS: A total of 462 patients underwent totally endoscopic robotic (n = 217) or transcatheter ASD closure (n = 245). Demographic data, perioperative data, and outcomes were compared.
RESULTS: The mean age was lower in the robotic surgery group than the transcatheter group (31.4 ± 11.8 vs 39.4 ± 13.2 years; P = .001). Ventilation time, intensive care unit (ICU) stay, and hospital stay was significantly lower in the transcatheter group. The postoperative new-onset neurological event was seen in one (0.5%) patient in robotic surgery, and four (1.6%) patients in the transcatheter closure group. New-onset atrial fibrillation was found to be higher in transcatheter closure (two vs seven patients; P = .133) group. Surgical conversion to a larger incision occurred in two patients (1%) in robotic surgery, while two patients (0.5%) underwent emergency median sternotomy due to device embolization to the main pulmonary artery. There was no mortality in both groups. During follow-up, one patient (0.5%) who underwent robotic surgery was reoperated, and two patients (0.8%) who underwent transcatheter procedure required surgical intervention due to device migration and severe residual shunting (P = .635).
CONCLUSION: Both transcatheter and robotic surgery approaches had excellent outcomes but transcatheter closure had shorter hospital and ICU stays. Robotic surgery provides a similar complication risk that can be comparable to the transcatheter approach as well as patient comfort and cosmetic advantage over the other surgical techniques.
© 2020 Wiley Periodicals, Inc.

Entities:  

Keywords:  atrial septal defect; minimally invasive; robotic surgery; transcatheter

Year:  2020        PMID: 32058626     DOI: 10.1111/jocs.14456

Source DB:  PubMed          Journal:  J Card Surg        ISSN: 0886-0440            Impact factor:   1.620


  5 in total

1.  A comparison of robotically-assisted endoscopic versus sternotomy approach for myxoma excision: A single-center experience.

Authors:  Ersin Kadiroğulları; Burak Onan; Ünal Aydın; Serdar Başgöze; Onur Şen
Journal:  Turk Gogus Kalp Damar Cerrahisi Derg       Date:  2020-07-28       Impact factor: 0.332

2.  Completed atrioventricular block induced by atrial septal defect occluder unfolding: A case report.

Authors:  Chuan He; Yang Zhou; Si-Si Tang; Li-Hong Luo; Kun Feng
Journal:  World J Clin Cases       Date:  2020-11-26       Impact factor: 1.337

Review 3.  Minimal access in cardiac surgery.

Authors:  Burak Onan
Journal:  Turk Gogus Kalp Damar Cerrahisi Derg       Date:  2020-10-21       Impact factor: 0.332

4.  Robotic Cardiac Surgery in Europe: Status 2020.

Authors:  Stepan Cerny; Wouter Oosterlinck; Burak Onan; Sandeep Singh; Patrique Segers; Cengiz Bolcal; Cem Alhan; Emiliano Navarra; Matteo Pettinari; Frank Van Praet; Herbert De Praetere; Jan Vojacek; Theodor Cebotaru; Paul Modi; Fabien Doguet; Ulrich Franke; Ahmed Ouda; Ludovic Melly; Ghislain Malapert; Louis Labrousse; Monica Gianoli; Alfonso Agnino; Tine Philipsen; Jean-Luc Jansens; Thierry Folliguet; Meindert Palmen; Daniel Pereda; Francesco Musumeci; Piotr Suwalski; Koen Cathenis; Jef Van den Eynde; Johannes Bonatti
Journal:  Front Cardiovasc Med       Date:  2022-01-20

5.  Total Thoracoscopic versus Robotic Surgery for Repair of Atrial Septum Defect: A Propensity Matching Score Analysis.

Authors:  Yanyi Liu; Zhuang Liu; Xin Li; Ning Li; Ruirui Kong; Yiyao Jiang; Shenglin Ge; Chengxin Zhang
Journal:  Emerg Med Int       Date:  2022-09-23       Impact factor: 1.621

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.